25May 2019

MALIGNANT SPINAL CORD COMPRESSION, EARLY CLINICAL OUTCOME.

  • Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, Suez Canal University, Egypt.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Introduction: Metastatic spinal cord compression (MSCC) is usually an oncological emergency and a well-recognized complication of cancer. Lung, prostate, multiple myeloma, non-Hodgkin lymphoma, and breast are the most common underlying tumors. These five types of malignancy, in addition to sarcomas and renal cancers account for about 70% of cases of metastatic epidural spinal cord compression. If untreated, metastatic epidural compression progresses, causing paralysis, sensory loss, and sphincter incontinence. Material and Methods: Prospective descriptive cross sectional study to assess prognostic factors and clinical outcome of malignant spinal compression among patients attending Suez Canal university hospital in period from 2016 to 2017. Results: A total of 48 patients were included in this study. Males accounting 45.8% and 54.2% were females. Breast cancer was the most incident (27%) to cause spinal cord compression. Dorsal vertebra was the most common site affected (45, 8%). Most of the studied patients (79.2%) presented with MSCC within less than 12 months from tumor diagnosis. 70.8% of studied population were managed by radiotherapy, 12.5% managed by surgery and 16.7% managed by both. The mean overall survival among the studied patients was 6.5 months. Conclusions: In Egypt, no documented data of incidence of MSCC. Most of MSCC cases (79%) were presented within less than 12 months from time of primary tumor diagnosis and that was significantly related to better post management functional outcome. After management of MSCC cases 50% showed improvement of motor function, no interval changes in (41.7%) and (8.3%) showed deterioration of motor function. After 6 months of follow up of MSCC 37.5% of cases have residual and 12.5% have recurrence or progression of disease.


  1. Abrahm, J. L. (2004). "Assessment and treatment of patients with malignant spinal cord compression." J Support Oncol 2(5): 377-388.
  2. Bach, F, Larsen BH, Rohde K, et al. (1990). "Metastatic spinal cord compression. Occurrence, symptoms, clinical presentation and prognosis " Actaneurochirurgica 107(1-2): 37-43.
  3. Bucholtz JD. ( 1999). Metastatic epidural spinal cord compression. SeminOncolNurs :15 3:150?159. [PubMed] [Google Scholar]
  4. David Schiff and Kathryn Nevel. (2011).metastatic spinal cord compression, epidemiology, section 7 of 14. 57.
  5. Douglas, S., Stefan Huttenlocher, AmiraBajrovic et al. (2012). "Prognostic factors for different outcomes in patients with metastatic spinal cord compression from cancer of unknown primary." BMC cancer 12:(1).
  6. Greyfriars Road, Cardiff. (2008). Metastatic spinal cord compression, the National Collaborating Centre for Cancer, CF10 3AF.
  7. Husband DJ, Grant KA and Romaniuk CS. (2001). MRI in the diagnosis and treatment of suspected malignant spinal cord compression. Br J Radiol; 74:15?23. [PubMed] [Google Scholar]
  8. Helweg-Larsen S, Sorensen PS, Kreiner S., et al. (2000). "Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients." International Journal of Radiation Oncology* Biology* Physics 46(5): 1163-1169.
  9. Ibrahim, A. S., Hussein M. Khaled, Nabiel NH Mikhail, et al. (2014). "Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program." Journal of Cancer Epidemiology: 18.
  10. Loblaw DA, Laperriere NJ and Mackillop WJ. (2003). "A population-based study of malignant spinal cord compression in Ontario." Clinical Oncology 15(4): 211-217.
  11. NaliniVadivelu, ‏Richard D. Urman and ‏Roberta L. Hines (2011) .Essentials of pain management: complete patient evaluation: motor strength evaluation: 65.
  12. Oken M, Creech R, Tormey D, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J ClinOncol.; 5:649-655.
  13. Quraishi, N. A. and C. Esler (2011). "Metastatic spinal cord compression." BMJ 342(7): d2402.
  14. White, B., et al. (2008). "Diagnosis and management of patients at risk of or with metastatic spinal cord compression: summary of NICE guidance." BMJ (CR)-print 337(7): a2538.
  15. Rasool M T., Kaneez Fatima, NajmiArshadManzoor, et al. (2016). "Profile of malignant spinal cord compression: One year study at regional cancer center." Indian journal of palliative care 22(2): 125.

[Maha L.zamzam and Marwa A.suliman. (2019); MALIGNANT SPINAL CORD COMPRESSION, EARLY CLINICAL OUTCOME. Int. J. of Adv. Res. 7 (May). 786-795] (ISSN 2320-5407). www.journalijar.com


Marwa A.suliman
Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, Suez Canal University, Egypt

DOI:


Article DOI: 10.21474/IJAR01/9100      
DOI URL: http://dx.doi.org/10.21474/IJAR01/9100